Short Interest in Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Declines By 30.9%

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) was the recipient of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 269,500 shares, a decline of 30.9% from the February 28th total of 389,900 shares. Approximately 1.6% of the shares of the company are sold short. Based on an average daily volume of 333,500 shares, the short-interest ratio is presently 0.8 days.

Analyst Ratings Changes

Separately, Maxim Group raised their price target on shares of Chemomab Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th.

Institutional Investors Weigh In On Chemomab Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new position in shares of Chemomab Therapeutics during the fourth quarter worth about $26,000. XTX Topco Ltd lifted its position in Chemomab Therapeutics by 63.8% in the 4th quarter. XTX Topco Ltd now owns 24,929 shares of the company’s stock valued at $45,000 after purchasing an additional 9,706 shares during the last quarter. Finally, Sphera Funds Management LTD. bought a new position in Chemomab Therapeutics in the 3rd quarter worth about $1,907,000. 46.05% of the stock is owned by institutional investors and hedge funds.

Chemomab Therapeutics Stock Up 2.7 %

Shares of NASDAQ:CMMB traded up $0.03 during trading on Friday, hitting $1.13. 98,410 shares of the company traded hands, compared to its average volume of 207,791. The stock has a market capitalization of $16.23 million, a price-to-earnings ratio of -1.13 and a beta of 0.54. Chemomab Therapeutics has a one year low of $0.58 and a one year high of $2.55. The business’s fifty day moving average is $1.70 and its 200-day moving average is $1.68.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).